Mirador Therapeutics announced an exclusive worldwide license agreement with Kira Pharmaceuticals for KP-301. The release provides no financial terms or milestone details, so near-term impact appears limited absent further disclosure on development and economics.
Mirador Therapeutics announced an exclusive worldwide license agreement with Kira Pharmaceuticals for KP-301. The release provides no financial terms or milestone details, so near-term impact appears limited absent further disclosure on development and economics.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
neutral
Sentiment Score
0.05
